1.      How long have you been a member of PGRN, and how did you first join PGRN? 

I joined PGRN on July 20, 2020. My joining was in a quest to satisfy my lack of knowledge in the field of pharmacogenomics due to my relentless pursuit in optimizing patient care within my institution, Federal Neuro-Psychiatric Hospital, Lagos, Nigeria.

2.      What is your current position/role, and what do you enjoy most about it?

As a clinical pharmacist, I encountered a persistent challenge; the variable response to psychotropic medications among patients, coupled with the occurrence of adverse drug reactions. Witnessing the financial strain and emotional toll this took on patients and their caregivers, along with the frustration among psychiatrists grappling with treatment decisions, stirred a passion within me to seek solutions.

As I wanted to learn more and make a difference, I jumped into precision medicine and pharmacogenetics. Even though my country didn't have much training or support, I didn't let that stop me. I believed in immersing myself in the global community of experts, which led me to become a member of PGRN from a developing country.

3.      How has PGRN helped your career in pharmacogenomics?

This affiliation has not only provided me with access to cutting-edge research and resources but also connected me with mentors whose guidance proved invaluable in navigating the complexities of pharmacogenetics. One such mentorship opportunity arose when I reached out to Akinyemi Oni-Orisan and Laura Ramsey. Their willingness to share their expertise and offer collaborative opportunities propelled my journey forward, reinforcing my belief in the power of mentorship and collaboration in driving innovation.

With the support of PGRN, I'm ready to address the issues in psychiatric treatment in my country and globally. My strong dedication to improving patient care with precision medicine keeps me motivated to push limits, explore new methods, and promote the use of pharmacogenetics.

4.      What do you see as the most exciting advances in pharmacogenomics over the next 2-5 years?

I'm excited about a big change in clinical pharmacogenetic testing becoming widely used in various medical specialties globally. I think this change will happen because clear, consistent, and comprehensive practice guidelines will be created. These guidelines will address more inclusion of under-represented populations with diverse genetic make-up, making sure everyone has fair access to these tests.

Global collaboration among researchers, clinicians, policymakers, and stakeholders is crucial for improving pharmacogenetic practices. By working together, we can bridge gaps, create a unified approach to gene-based therapies, and enhance healthcare. This effort aims to bring innovation, accessibility, and inclusivity, ushering in a new era of healthcare excellence where everyone gets personalized treatments based on their genetic makeup and medical needs.

5.      If there are no restrictions to travel, where would you like to go in the next 3-6 months?

I would pick the Maldives. The idea of being on these private islands with powdery white sand and distinct white beaches is an exciting prospect. Staying in one of those fancy overwater bungalows, stepping right into the clear lagoon – it would be a dream come true for me.

6.      What’s something about you (a fun fact) not many people know?

My participation in the Calypso dance club in elementary school. It all began with a spontaneous decision to try something new, from learning the lively steps of traditional Caribbean dances to performing in front of a cheering audience during school events, every moment spent in the Calypso dance club was filled with excitement and a sense of accomplishment.